Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.
Active surveillance is an established option for men with low risk prostate cancer. Multiparametric magnetic resonance imaging with magnetic resonance imaging-transrectal ultrasound fusion guided biopsy may better identify patients for active surveillance compared to systematic 12-core biopsy due to improved risk stratification. To our knowledge the performance of multiparametric magnetic resonance imaging in following men on active surveillance with visible lesions is unknown. We evaluated multiparametric magnetic resonance imaging and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy to monitor men on active surveillance.



This retrospective review included men from 2007 to 2015 with prostate cancer on active surveillance in whom magnetic resonance imaging visible lesions were monitored by multiparametric magnetic resonance imaging and fusion guided biopsy. Progression was defined by ISUP (International Society of Urological Pathology) grade group 1 to 2 and ISUP grade group 2 to 3. Significance was considered at p ≤0.05.



A total of 166 patients on active surveillance with 2 or more fusion guided biopsies were included in analysis. Mean followup was 25.5 months. Of the patients 29.5% had pathological progression. Targeted biopsy alone identified 44.9% of patients who progressed compared to 30.6% identified by systematic 12-core biopsy alone (p = 0.03). Fusion guided biopsy detected 26% more cases of pathological progression on surveillance biopsy compared to systematic 12-core biopsy. Progression on multiparametric magnetic resonance imaging was the sole predictor of pathological progression at surveillance biopsy (p = 0.013). Multiparametric magnetic resonance imaging progression in the entire cohort had 81% negative predictive value, 35% positive predictive value, 77.6% sensitivity and 40.5% specificity in detecting pathological progression.



Multiparametric magnetic resonance imaging progression predicts the risk of pathological progression. Patients with stable multiparametric magnetic resonance imaging findings have a low rate of progression. Incorporating fusion guided biopsy in active surveillance nearly doubled our detection of pathological progression compared to systematic 12-core biopsy.
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Thomas P
TP
Frye
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Arvin K
AK
George
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Amichai
A
Kilchevsky
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Mahir
M
Maruf
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
M Minhaj
MM
Siddiqui
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Michael
M
Kongnyuy
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Akhil
A
Muthigi
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Hui
H
Han
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Howard L
HL
Parnes
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Maria
M
Merino
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Peter L
PL
Choyke
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Baris
B
Turkbey
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland.
Brad
B
Wood
Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland. Electronic address: pintop@mail.nh.gov.
Peter A
PA
Pinto
D000368:Aged; D018450:Disease Progression; D006801:Humans; D061705:Image-Guided Biopsy; D053783:Magnetic Resonance Imaging, Interventional; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*; D012189:Retrospective Studies; D018084:Ultrasonography, Interventional
biopsy; magnetic resonance imaging; prostatic neoplasms; ultrasonography; watchful waiting